Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study
| Autor: | María Guadalupe Zavala-Cerna, N. A. Rodriguez-Jimenez, José Clemente Vásquez-Jiménez, Arnulfo Hernán Nava-Zavala, Jorge I. Gamez-Nava, Mario Salazar-Páramo, Valeria Diaz-Rizo, Aniel Jessica Leticia Brambila-Tapia, Mónica Vázquez-Del Mercado, Ernesto Germán Cardona-Muñoz, Alberto Daniel Rocha-Muñoz, Ingrid Patricia Dávalos-Rodríguez, Laura Gonzalez-Lopez, Liliana Faviola De la Cerda-Trujillo, Viviana Díaz-González |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male musculoskeletal diseases lcsh:Immunologic diseases. Allergy Vital capacity medicine.medical_specialty Article Subject Immunology Vital Capacity Pulmonary function testing FEV1/FVC ratio immune system diseases Internal medicine medicine Immunology and Allergy Humans Spondylitis Ankylosing skin and connective tissue diseases Spondylitis BASDAI Aged Ankylosing spondylitis business.industry Tumor Necrosis Factor-alpha Antibodies Monoclonal General Medicine Middle Aged medicine.disease Respiratory Function Tests respiratory tract diseases Antirheumatic Agents Treatment Outcome Physical therapy Clinical Study Drug Therapy Combination Female BASFI business lcsh:RC581-607 Follow-Up Studies |
| Zdroj: | Journal of Immunology Research, Vol 2015 (2015) Journal of Immunology Research |
| ISSN: | 2314-7156 2314-8861 |
| Popis: | Objective. To evaluate the effect of anti-TNF agents plus synthetic disease modifying antirheumatic drugs (DMARDs) versus DMARDs alone for ankylosing spondylitis (AS) with reduced pulmonary function vital capacity (FVC%).Methods. In an observational study, we included AS who had FVC% Results. Both DMARDs and anti-TNF + DMARDs groups had similar baseline values in FVC%. Significant improvement was achieved with anti-TNF + DMARDs in FVC%, at 24 months, when compared to DMARDs alone (P=0.04). Similarly, patients in anti-TNF + DMARDs group had greater improvement in BASDAI, BASFI, Borg scale, and 6MWT when compared to DMARDs alone. After 2 years of follow-up, 14/16 (87.5%) in the anti-TNF + DMARDs group achieved the primary outcome: FVC% ≥80%, compared with 11/20 (55%) in the DMARDs group (P=0.04).Conclusions. Patients with anti-TNF + DMARDs had a greater improvement in FVC% and cardiopulmonary scales at 24 months compared with DMARDs. This preliminary study supports the fact that anti-TNF agents may offer additional benefits compared to DMARDs in patients with AS who have reduced FVC%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|